Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer
PERSONALIZED MEDICINE, cilt.19, sa.5, ss.435-444, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 5
- Basım Tarihi: 2022
- Doi Numarası: 10.2217/pme-2021-0047
- Dergi Adı: PERSONALIZED MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
- Sayfa Sayıları: ss.435-444
- Anahtar Kelimeler: adverse effects, colorectal cancer, DPYD, fluoropyrimidines, MTHFR, pharmacogenetics, polymorphisms, TYMS, DIHYDROPYRIMIDINE DEHYDROGENASE GENE, METHYLENETETRAHYDROFOLATE REDUCTASE, THYMIDYLATE-SYNTHASE, CAPECITABINE, VARIANTS, METABOLISM, EFFICACY, PREDICT, PHARMACOKINETICS, DPYD-ASTERISK-2A
- Marmara Üniversitesi Adresli: Evet
Özet
Aim: To investigate the association of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil (5-FU) related toxicities and patient survival. Materials & methods: A total of 103 colorectal cancer patients prescribed 5-FU were included in the study. Genotyping was conducted for several DPYD, MTHFR and TYMS polymorphisms using a microarray analyzer. Results: DPYD 496A>G polymorphism was found to be significantly associated with 5-FU related grade 0-2, but not severe toxicities (p = 0.02). Furthermore, patients with DPYD 85TC and CC genotypes had longer progression and overall survival times compared to TT genotypes in our study group (log rank = 6.60, p = 0.01 and log rank = 4.40, p = 0.04, respectively). Conclusion: According to our results, DPYD 496AG and GG genotypes might be protective against severe adverse events compared to the AA genotype. Another DPYD polymorphism, 85T>C, may be useful in colorectal cancer prognosis. Further studies for both polymorphisms should be conducted in larger populations to achieve accurate results.